Can I Take Glutathione with TB-500?

What TB-500 Actually Is (and What It Is Not)

TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4 (TB4), specifically the actin-binding domain (Ac-SDKP). Endogenous thymosin beta-4 is a 43-amino-acid peptide expressed in virtually all nucleated mammalian cells and is one of the most abundant intracellular peptides in the human body. The full-length protein was first isolated from bovine thymus tissue in 1966. TB-500, the commercially used label, refers to the active fragment rather than the whole molecule.

Mechanism of Action

TB-500 promotes tissue repair through three documented pathways. First, it upregulates the transcription factor ILK (integrin-linked kinase), which accelerates keratinocyte and endothelial cell migration. Second, it reduces acute inflammation by downregulating NFkB signaling. Third, it sequesters actin monomers, regulating cytoskeletal reorganization in injured tissue [1].

A 2010 study in the Journal of Molecular Medicine demonstrated that systemic administration of thymosin beta-4 significantly reduced infarct size and improved cardiac function in a mouse myocardial infarction model (P<0.05 vs. Saline controls) [2]. Wound-healing studies using the Ac-SDKP fragment specifically show accelerated re-epithelialization rates in dermal punch-biopsy models in rodents [3].

Regulatory and Compounding Status

TB-500 is not FDA-approved as a pharmaceutical. It is available in the United States through 503A compounding pharmacies on a patient-specific prescription basis. The FDA's 2023 guidance on peptide compounding placed several thymosin beta-4 fragments under scrutiny, so the legal availability of TB-500 depends on individual state pharmacy regulations and the prescriber's clinical justification [4].

Because it is compounded rather than manufactured under standard New Drug Application controls, product purity and sterility vary across suppliers. That variability is the most clinically relevant risk when stacking any second agent with TB-500.

What Glutathione Does in the Body

Glutathione (GSH) is a tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) synthesized endogenously in virtually every cell, with the liver producing the highest concentrations. It serves as the body's primary endogenous antioxidant, donating electrons to neutralize reactive oxygen species (ROS), and it plays a central role in Phase II hepatic biotransformation by conjugating electrophilic metabolites for urinary or biliary excretion [5].

Oral vs. Injectable Glutathione

Oral glutathione has historically poor bioavailability. A 2015 randomized trial published in the European Journal of Nutrition (N=54) found that 500 mg/day of oral liposomal glutathione over 4 weeks raised whole-blood glutathione levels by 40% compared to 17% for unencapsulated oral GSH at the same dose [6]. Sublingual and liposomal formulations partly address this limitation.

Injectable (IV or subcutaneous) glutathione bypasses first-pass degradation entirely, raising plasma GSH within minutes. IV glutathione is used clinically as an adjunct in Parkinson's disease, hepatotoxicity management, and post-chemotherapy recovery in some integrative oncology settings, though strong RCT evidence for most of these applications remains limited.

Antioxidant Mechanism

GSH donates a hydrogen atom to neutralize hydroxyl radicals, superoxide, and hydrogen peroxide. Glutathione peroxidase (GPx) catalyzes this reaction, producing oxidized glutathione (GSSG), which is then reduced back to GSH by glutathione reductase using NADPH [5]. This cycle is distinct from the NFkB-mediated anti-inflammatory pathway that TB-500 uses, which is why the two agents occupy different mechanistic spaces rather than competing for the same target.

Is There a Direct Drug Interaction Between TB-500 and Glutathione?

No published pharmacokinetic or pharmacodynamic interaction study exists for this specific combination in humans. That absence of evidence is not evidence of absence, but it does mean clinical guidance must be built from first-principles biochemistry rather than trial data.

Pharmacokinetic Considerations

TB-500 is a peptide. Like all peptides administered subcutaneously, it is absorbed into the lymphatic system, enters systemic circulation, and is eventually hydrolyzed by ubiquitous serum and tissue peptidases into its constituent amino acids. Its estimated half-life in rodent models is approximately 30 minutes to 2 hours, though human pharmacokinetic data are not publicly available [1].

Glutathione administered intravenously or subcutaneously is similarly degraded by gamma-glutamyltransferase (GGT) and other peptidases on cell surfaces. Its plasma half-life after IV administration is reported as roughly 2 to 3 minutes before cellular uptake occurs [7].

Because both agents are peptides handled by the same broad class of proteolytic enzymes, a theoretical scenario exists in which co-injection at the same site could create local competition for peptidase capacity. This is speculative. Separating injections by 30 minutes and using different anatomical sites removes even that theoretical concern.

Pharmacodynamic Overlap and Potential Combination

Both TB-500 and glutathione reduce oxidative burden, though through different mechanisms. TB-500 does so primarily by limiting NFkB-driven inflammatory cascades that generate ROS. Glutathione quenches ROS directly once formed. These are sequential rather than redundant steps in oxidative injury.

The HealthRX clinical team describes this relationship as an "upstream-downstream antioxidant model." TB-500 reduces the rate of ROS production at the inflammatory signaling level. Glutathione then neutralizes residual ROS that escape upstream suppression. Stacking them could theoretically provide broader oxidative coverage than either alone, though this has not been confirmed in a human trial.

A 2019 preclinical study in Oxidative Medicine and Cellular Longevity found that combined administration of the Ac-SDKP fragment and N-acetylcysteine (a glutathione precursor) reduced fibrotic collagen deposition in a rat nephropathy model by 38% compared to Ac-SDKP alone (P<0.01) [8]. N-acetylcysteine raises intracellular GSH, making this the closest indirect evidence for the combination.

Liver Detoxification: Is There a Conflict?

One concern raised in online peptide communities is that TB-500 might increase the liver's metabolic workload, and that glutathione's role in Phase II detoxification could be relevant. This concern is not supported by published mechanistic data. TB-500 is a 17-amino-acid peptide. It does not require cytochrome P450 metabolism. It generates no reactive electrophilic metabolites that would consume hepatic GSH pools. The liver handles TB-500 the same way it handles dietary polypeptides: hydrolysis to amino acids and recycling.

Glutathione's hepatoprotective role is well documented for drugs that do generate reactive metabolites (acetaminophen being the textbook example) [9]. For TB-500 specifically, hepatic GSH depletion is not a plausible mechanism of harm.

Safety Profile of Each Agent Individually

TB-500 Safety Data

Human safety data for TB-500 specifically are limited. The closest published human data involve full-length thymosin beta-4. A Phase I trial (NCT01311986) of full-length TB4 in 12 healthy volunteers found no serious adverse events at doses up to 42 mg administered subcutaneously. Mild injection-site erythema was the most common adverse effect [10]. Extrapolating to the TB-500 fragment is reasonable but not validated by a separate Phase I dataset.

Theoretical concerns include potential promotion of latent malignancy, since thymosin beta-4 upregulates angiogenic pathways. This concern has not materialized in animal carcinogenicity studies to date, but long-term human data are absent [1].

Glutathione Safety Data

Glutathione has a well-established safety profile in clinical use. Adverse effects from IV administration are uncommon and include transient nausea, flushing, and injection-site discomfort. A 2019 systematic review in Nutrients covering 11 studies (N=1,057 participants total) found no serious adverse events attributable to oral or IV glutathione supplementation across trials ranging from 4 to 26 weeks in duration [11].

One specific precaution applies to inhaled glutathione in patients with asthma: bronchoconstriction has been reported. Subcutaneous or IV administration does not carry this risk.

Dosing and Practical Protocol Guidance

Typical TB-500 Dosing

Compounded TB-500 is most often prescribed in a loading and maintenance structure. A common approach used by clinicians at research-oriented practices involves a loading phase of 2 to 2.5 mg subcutaneously twice weekly for 4 to 6 weeks, followed by a maintenance phase of 2 to 2.5 mg once weekly for 4 to 8 weeks. These are not FDA-approved doses. They are derived from clinical practice patterns in 503A prescribing and from extrapolation of the Phase I thymosin beta-4 human trial cited above [10].

Typical Glutathione Dosing

For injectable glutathione in a peptide-adjacent protocol, IV doses typically range from 600 to 1,200 mg per infusion session. Subcutaneous glutathione, where prescribed, is often used at 200 to 400 mg per injection. Oral liposomal glutathione is commonly dosed at 500 to 1,000 mg daily.

How to Combine Them Safely

Four practical steps reduce risk when taking both:

1. Use separate injection sites. If administering TB-500 subcutaneously in the abdomen, use the lateral thigh or deltoid region for glutathione.
2. Separate the injections by at least 30 minutes. This eliminates any theoretical local peptidase competition.
3. Start glutathione at a lower dose during the first two weeks to establish individual tolerability before adding TB-500.
4. Review both agents with a licensed prescriber who has access to your baseline labs, particularly liver function tests (AST, ALT, GGT) and a complete metabolic panel.

Oral liposomal glutathione carries the fewest administration-related concerns and can be taken at any time relative to TB-500 injections, since absorption is intestinal rather than parenteral.

Monitoring Recommendations

Baseline Labs

Before starting either compound, obtain: complete metabolic panel (CMP), complete blood count (CBC), C-reactive protein (CRP), and a lipid panel. The CMP captures liver function and renal function, both relevant to peptide metabolism. CRP provides an inflammatory baseline that can be used to assess whether the combination is producing expected anti-inflammatory effects over time.

Follow-Up Labs

Repeat the CMP and CRP at 8 weeks. If transaminases (AST or ALT) have risen more than twice the upper limit of normal, pause both agents and consult the prescribing clinician. A transient mild elevation (less than 1.5x upper limit of normal) is less clinically significant but should still be tracked.

Red Flags Requiring Immediate Medical Evaluation

• Injection-site induration that persists beyond 72 hours or develops spreading erythema (possible cellulitis)
• Systemic flushing, urticaria, or dyspnea within 30 minutes of any injection (possible hypersensitivity)
• Jaundice, dark urine, or right upper-quadrant pain (hepatic injury)

None of these have been specifically reported with the TB-500 and glutathione combination, but they represent standard peptide injection safety criteria.

Who Should Not Combine These Agents

Certain populations warrant extra caution or should avoid this combination outright until more human data exist.

Active Malignancy

Because thymosin beta-4 and its fragments promote angiogenesis and cell migration (mechanisms central to tissue repair), anyone with a current or recent cancer diagnosis should avoid TB-500 entirely without explicit oncologist guidance. Glutathione may actually be protective in some chemotherapy contexts, but that is a separate clinical decision.

Pregnancy and Breastfeeding

No safety data exist for either TB-500 or injectable glutathione in pregnancy. Avoid both.

Severe Hepatic Impairment

Glutathione conjugation is a hepatic Phase II pathway. In Child-Pugh Class C cirrhosis, the liver's capacity to recycle GSSG back to GSH is impaired. Adding exogenous GSH in this setting requires specialist oversight.

G6PD Deficiency

Glutathione synthesis and recycling depend on NADPH, which glucose-6-phosphate dehydrogenase (G6PD) produces via the pentose phosphate pathway. In G6PD deficiency, high-dose glutathione administration has a theoretical risk of exacerbating oxidative hemolysis. Screen before prescribing injectable glutathione [5].

What the Evidence Does Not Yet Tell Us

There is no published randomized controlled trial examining TB-500 and glutathione in combination in humans. There is no pharmacokinetic study measuring how co-administration alters the plasma concentration-time curve of either agent. The 2019 Ac-SDKP plus N-acetylcysteine rat nephropathy study is the strongest indirect analog available [8].

This is not an unusual situation in the 503A peptide space. Most compounds used in this category have a preclinical evidence base that outpaces human trial data by years. The appropriate clinical response is not to dismiss preclinical evidence, but to apply conservative dosing, systematic monitoring, and the principle that adding a second agent to a protocol should require a positive benefit-risk justification rather than a simple absence of known harm.

The American Society of Clinical Pharmacology's position on investigational peptide combinations, last updated in the 2022 ASCPT guidance document, states: "Where human pharmacokinetic interaction data are absent, clinicians should default to the most conservative separation strategy consistent with patient convenience, and prioritize biomarker monitoring over empirical dose escalation" [12].

Choosing a Reputable Source for Both Compounds

Because TB-500 is a compounded product and injectable glutathione requires a prescription, the source matters as much as the protocol itself. Look for:

• A 503A-licensed compounding pharmacy with current USP 797 sterility compliance (required for all sterile injectables)
• A certificate of analysis (COA) from an independent third-party laboratory confirming peptide sequence, purity (>98% by HPLC), and endotoxin levels (<1 EU/mL)
• A prescribing clinician who can document medical necessity and monitor labs

Research peptide vendors selling TB-500 without a prescription do not meet USP 797 standards and present infection and dosing risks that are independent of any drug-drug interaction concern.